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A B S T R A C T
Background: Although gender may be one of the important factors modifying phenotypic expression in
hypertrophic cardiomyopathy (HCM), there has been little information on it.
Methods and results: We investigated gender differences in the clinical features of HCM caused by
cardiac myosin-binding protein C gene (MYBPC3) mutations. Sixty-one subjects (28 families) carrying
MYBPC3 mutations were studied. Of the 61 subjects with MYBPC3 mutations, 50 patients including
23 female patients were phenotype-positive by echocardiography. Disease penetrance in subjects aged
40 years old was 92% in males and 67% in females. Females showed delayed onset of left ventricular
hypertrophy compared with males in subjects who were genotype-positive. Female patients were more
symptomatic at diagnosis than were males (mean New York Heart Association class: 1.7  0.8 versus
1.2  0.4, p = 0.012). From a longitudinal point of view by age, no signiﬁcant gender difference in
cardiovascular deaths or cardiovascular events was found. During the follow-up period after diagnosis of
HCM (13  8 years), female patients who were phenotype-positive had signiﬁcantly more frequent heart
failure events than did phenotypically affected male patients (p = 0.028).
Conclusions: Although females with MYBPC3 mutations showed later onset of the disease, female
patients were more symptomatic at diagnosis and had more frequent heart failure events once they had
developed hypertrophy.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Hypertrophic cardiomyopathy (HCM) is a primary and geneti-
cally transmitted myocardial disorder characterized by thickening
of the left ventricular (LV) wall in the absence of another cardiac or
systemic disease capable of producing the magnitude of evident
hypertrophy [1–9]. HCM is usually caused by sarcomere protein
gene mutations, and the cardiac phenotype has great diversity in
morphologic features, age of onset, and clinical course [1–9]. This
phenotypic heterogeneity suggests the existence of some factors
that modify the disease presentation. Gender is thought to be one
of the important modifying factors in HCM because female patients* Corresponding author at: Department of Cardiology, Neurology and Aging
Science, Kochi Medical School, Oko-cho, Nankoku-shi, Kochi 783-8505, Japan.
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0914-5087/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightswith HCM had been reported to be older and more symptomatic
than male patients at the time of their initial diagnosis [10–14].
These gender-speciﬁc differences can be explained by social,
endocrine, or genetic factors. However, there has been little
information on gender differences in HCM patients carrying
sarcomere protein gene mutations [10]. In this study, we
investigated the gender differences in clinical features of familial




We studied 28 HCM families with disease-causing MYBPC3
mutations at Kochi Medical School Hospital. The diagnosis of HCM
was based on echocardiographic demonstration of unexplained
left ventricular hypertrophy (LVH), i.e. maximum LV wall thickness reserved.
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Fig. 1. Flowchart of this study. HCM, hypertrophic cardiomyopathy.
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probands themselves and visited our clinic of their own free will.
Following the identiﬁcation of mutations, pedigree analysis
including both clinical evaluation and genotyping was performed.
Informed consent was obtained from all subjects or their parents in
accordance with the guidelines of the Ethics Committee on Medical
Research of Kochi Medical School.
Clinical evaluation
Evaluation of patients included medical history, clinical exami-
nation, 12-lead electrocardiography (ECG), and conventional and
Doppler echocardiography. The diagnosis of phenotype-positive,Table 1
Baseline characteristics in 50 HCM patients who were phenotype-positive at diagnosis
Total (n = 50) M
Age at diagnosis (years) 47  17 
Reason for diagnosis: symptoms, n (%) 23 (46%) 
Symptoms at diagnosis, n (%)
Presence of symptoms 28 (56%) 
Chest pain 11 (22%) 
Palpitation 15 (30%) 
Syncope 4 (8%) 
NYHA functional class 
I 32 (64%) 
II 14 (28%) 
III and IV 4 (8%) 
Mean NYHA functional class 1.4  0.6 
Presence of AF at diagnosis, n (%) 6 (12%) 
Maximum LV wall thickness (mm) 21  5 
Interventricular wall thickness (mm) 18  5 
Posterior wall thickness (mm) 11  2 
LV end-diastolic diameter (mm) 44  7 
Fractional shortening (%) 41  9 
Global ejection fraction (%) 66  10 
Left atrial diameter (mm) 40  8 
Dilated phase of HCM, n (%) 4 (8%) 
Presence of LV outﬂow obstruction, n (%) 8 (16%) 
Data were expressed as mean  SD or frequency (percentage). Differences in continuous
compare noncontinuous variables, and Fisher’s exact test was used when expected freq
HCM, hypertrophic cardiomyopathy; NYHA, New York Heart Association; AF, atrial ﬁbrithat is clinical diagnosis of HCM, was based on echocardiographic
demonstration of unexpected LVH (maximum LV wall thickness
15 mm). LV end-diastolic diameter (LVEDD) and end-systolic
diameter (LVESD) were measured from M-mode and 2D images
obtained from parasternal long-axis views, and fractional shorten-
ing [%FS = (LVEDD  LVESD)/LVEDD  100] was calculated. Global
ejection fraction (EF) was estimated from apical two- and four-
chamber views using modiﬁed Simpson’s method. Left ventricular
outﬂow tract obstruction (LVOTO) was deﬁned by the presence of a
basal peak subaortic gradient 30 mmHg calculated from continu-
ous-wave Doppler using the simpliﬁed Bernoulli equation. Dilated
phase of HCM was deﬁned as LV systolic dysfunction of global
EF < 50%. Concomitant coronary artery disease was excluded by
coronary angiography and/or myocardial scintigraphy.
For survival analysis, three modes of HCM-related death were
deﬁned: (1) sudden and unexpected death, in which collapse
occurred in the absence of or <1 h from the onset of symptoms in
patients who previously experienced a relatively stable or unevent-
ful clinical course; (2) heart failure-related death, which was in the
context of progressive cardiac decompensation 1 year before
death, particularly if complicated by pulmonary edema or evolution
to the end-stage phase; and (3) stroke-related death, which occurred
as a result of probable or proven embolic stroke. Other morbid
events included (1) hospitalization for heart failure, (2) embolic
stroke admission, (3) spontaneous sustained ventricular tachycardia
associated with hemodynamic instability or appropriate implant-
able cardioverter deﬁbrillator discharge, and (4) progression to New
York Heart Association (NYHA) functional class III or IV status, which
required additional treatment. Data on survival and clinical status of
patients were obtained during serial clinic visits or by direct
communication with patients and their cardiologists for patients
who were followed up at other institutions.
Genetic analysis
For genetic analysis, peripheral blood samples were taken at the
time of clinical evaluation, and they were frozen and stored at
20 8C. Deoxyribonucleic acid (DNA) was extracted using a DNA
puriﬁcation kit from QIAGEN Inc. (no. 51104; Hilden, Germany). In.
ale patients (n = 27) Female patients (n = 23) p
45  14 50  19 0.295
9 (33%) 14 (61%) 0.052
13 (48%) 15 (65%) 0.226
5 (19%) 6 (26%) 0.520
9 (33%) 6 (26%) 0.577
1 (4%) 3 (13%) 0.322
0.028
21 (78%) 11 (48%)
6 (22%) 8 (35%)
0 (0%) 4 (17%)
1.2  0.4 1.7  0.8 0.012
3 (11%) 3 (13%) 0.834
21  5 20  4 0.647
19  5 17  5 0.168
11  2 10  2 0.060
45  8 42  7 0.108
42  8 40  10 0.553
65  9 67  11 0.446
41  7 40  9 0.553
1 (4%) 3 (13%) 0.322
3 (11%) 5 (22%) 0.444
 variables were assessed using Student’s t-test. Pearson’s chi-square test was used to
uency was lower than 5.
llation; LV, left ventricular.
Fig. 2. Disease penetrance. (A) Disease penetrance in subjects. (B) Kaplan–Meier
event-free curves of cardiac disease penetrance stratiﬁed by gender.
Table 2






HCM-related deaths, n (%) 5 (19%) 3 (13%)
All HCM-related events, n (%) 7 (26%) 11 (48%)
Heart failure events, n (%) 5 (19%) 10 (43%)
HCM, hypertrophic cardiomyopathy.
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polymerase chain reaction (PCR). Oligonucleotide primers were
used to amplify protein-encoding exons of MYBPC3. Information on
primer sequences and PCR conditions is available upon request.
Direct sequencing was performed and the data of sequences were
analyzed on an ABI PRISM 3100-Avant Genetic Analyzer (Life
Technologies, Carlsbad, CA, USA) in accordance with the manual of
the manufacturer. In patients in whom mutation was identiﬁed,
conﬁrmation was obtained by re-analysis with direct sequencing
from a second blood sample. Disease-causing mutations were
based on presence of the mutation in all affected individuals and
absence of the sequence variation in at least 200 chromosomes
from healthy individuals.
Statistical analysis
Data were expressed as mean  SD or frequency (percentage).
Differences in continuous variables were assessed using Student’s t-
test. Pearson’s chi-square test was used to compare noncontinuous
variables, and Fisher’s exact test was used when expected frequency
was lower than 5. Survival estimates were calculated by the Kaplan–
Meier method, and the log rank test was used for comparison.
Statistical signiﬁcance was deﬁned by p < 0.05. Calculations were




In the 28 HCM families, a total of 61 subjects had MYBPC3
mutations (S297X in two families: three males and six females,
V593fs in 23 families: 27 males and 22 females, and R945fs in three
families: one male and two females) [15–18] (Fig. 1). Of the 61
subjects with mutations, 50 patients were phenotype-positive by
echocardiography (maximum LV wall thickness 15 mm); two of
them developed hypertrophy (phenotype-positive) during the
follow-up period after the identiﬁcation of genotype-positive.
Twenty-three (46%) of those phenotype-positive patients were
female. Of the 50 phenotype-positive patients, 23 patients (46%)
were diagnosed because of symptoms and 27 patients (54%) were
evaluated because of incidental ﬁndings, including ECG abnormal-
ities, systolic murmur, and family screening (Table 1). At diagnosis,
28 patients (56%) had some symptoms and 6 patients (12%) had
documentation of paroxysmal or chronic atrial ﬁbrillation.
Disease penetrance
The average ages at diagnosis were 45  14 years in males and
50  19 years in females. The disease penetrance in subjects aged
40 years old was 92% in males and 67% in females (Fig. 2A). Fig. 2B
shows Kaplan–Meier event-free curves of cardiac disease penetrance
stratiﬁed by gender. The disease penetrance was age-dependent, and
females showed delayed onset of LVH compared with males in
subjects who were genotype-positive.
Gender differences in patients with phenotype-positive
In patients who were phenotype-positive, female patients were
more symptomatic at diagnosis than males, with mean NYHA class
in female patients at diagnosis being 1.70  0.77 and that in males
being 1.22  0.42 (p = 0.012) (Table 1). Moreover, female patients
already had NYHA class III or IV symptoms at diagnosis more
frequently than did males.
Echocardiographic data for the 50 patients who were pheno-
type-positive at diagnosis showed that females tended to havesmaller LV size and a thinner LV posterior wall than those in
males, but no signiﬁcant differences were observed between the
genders. There was no signiﬁcant gender difference in the number
of end-stage HCM patients or number of HCM patients with
LVOTO.
Outcomes
There was no HCM-related cardiovascular event in phenotype-
negative subjects with MYBPC3 mutations (n = 11). Table 2 shows
the clinical events in the 50 patients who were phenotype-positive.
Fig. 3. Kaplan–Meier event-free curves after diagnosis of HCM according to phenotype-positive patients for survival free from (A) HCM-related death, (B) HCM-related
cardiovascular events and (C) HCM-related heart failure events. The blue curve indicates genotype-positive males and the red curve indicates genotype-positive females.
HCM, hypertrophic cardiomyopathy. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of the article.)
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difference was found for genotype-positive patients (n = 61) in
HCM-related deaths, HCM-related cardiovascular events, or heart
failure events. There was also no signiﬁcant gender difference by age
for phenotype-positive patients (n = 50) in HCM-related deaths,
HCM-related cardiovascular events, or heart failure events. Howev-
er, during the follow-up period after diagnosis of HCM (13  8 years),
female patients who were phenotype-positive had signiﬁcantly moreTable 3
Clinical complications and treatment in 50 HCM patients who were phenotype-positiv
Male patients (n = 27) 
Age at ﬁnal evaluation (years) 59  16 
Presence of atrial ﬁbrillation, n (%) 7 (26%) 
Presence of VT or NSVT, n (%) 7 (26%) 
Dilated phase of HCM, n (%) 5 (19%) 
Invasive treatments, n (%) 2 (7%) 
Medications, n (%)
ACEI or ARB, n (%) 9 (33%) 
Beta blockers, n (%) 14 (52%) 
Diuretics, n (%) 6 (22%) 
Data were expressed as mean  SD or frequency (percentage). Differences in continuous
compare noncontinuous variables, and Fisher’s exact test was used when expected freq
HCM, hypertrophic cardiomyopathy; VT, ventricular tachycardia; NSVT, nonsustained
angiotensin II receptor blockers.frequent heart failure events than did phenotypically affected male
patients (p = 0.028) (Fig. 3). Table 3 shows the clinical complications
and treatment in the 50 patients who were phenotype-positive.
Discussion
HCM is a primary and genetically transmitted myocardial
disorder, usually caused by mutations in the genes that encodee during follow-up period.
Female patients (n = 23) p








 variables were assessed using Student’s t-test. Pearson’s chi-square test was used to
uency was lower than 5.
 ventricular tachycardia; ACEI, angiotensin-converting enzyme inhibitors; ARB,
Y. Terauchi et al. / Journal of Cardiology 65 (2015) 423–428 427sarcomere contractile proteins and genetically transmitted with a
Mendelian autosomal dominant pattern of inheritance, with a
broad spectrum of morphologic features and clinical presentations
[1–9]. The cardiac phenotype of HCM shows marked diversity in
the degree and pattern of LVH, age of onset, and clinical course.
This phenotypic heterogeneity can be established by genetic
factors, including private disease-causing mutations and poly-
morphisms, and by environmental factors. As previously reported,
gender-speciﬁc differences have been shown in acquired cardio-
vascular diseases, including coronary heart disease, atrial ﬁbrilla-
tion, and stroke. However, there have been few studies in which
gender-related differences in the clinical features of HCM were
investigated, and knowledge about gender-related differences in
cardiac manifestations in sarcomere gene mutation carriers is
lacking [10–14].
Several studies have shown that women with HCM had delayed
onset of symptoms and clinical identiﬁcation compared with those
in men [10,13,19,20]. Some possible explanations for this
difference in diagnostic age by gender are (1) different medical
screening systems, (2) clinician bias, and (3) different penetrance
between the two genders. In our genotyped cohort, factors such as
different medical screening systems and clinician bias were
considered to be excluded as much as possible. This study
conﬁrmed a high cardiac disease penetrance in MYBPC3 mutation
carriers in females and males. Furthermore, the age-dependent
penetrance of LVH was even higher in men than in women. A
recent large genotyped-cohort study by Page et al. reported the
same ﬁnding that disease penetrance was higher in males than in
females [21]. Women may have some mechanisms, such as genetic
(modiﬁer genes on the sex chromosome) and sexual hormonal
factors, that prevent the development of hypertrophy, resulting in
later onset of disease. Indeed, estrogen through estrogen receptor
activation might modulate hypertrophic signaling in females, since
estrogen treatment reduced myocardial hypertrophy in animal
models [22].
Compared to male patients, female patients were more
symptomatic at diagnosis in our genotyped cohort. Furthermore,
from a longitudinal point of view by age, no signiﬁcant gender
difference in HCM-related adverse events was found in either
genotype-positive patients or phenotype-positive patients. How-
ever, during the follow-up period from after diagnosis of HCM,
once LVH had developed, female patients had signiﬁcantly more
frequent heart failure events than did phenotypically affected male
patients. Although the reasons for these ﬁndings are not obvious,
Olivotto et al. also reported in their longitudinal study that female
patients were more symptomatic and that female gender was
independently associated with risk of symptom progression to
NYHA functional class III/IV or death from heart failure or stroke
compared with male gender [13].
There are several limitations to be acknowledged in the present
study. First, due to the retrospective design of the study, it is
possible that there is a selection bias. Second, the number of
subjects was small and the distribution of the MYBPC3 mutations
was skewed in our genotyped cohort. Some of the statistical
analyses might have been affected. Unfortunately, multivariate
analysis was not used to evaluate the prognostic values of these
clinical proﬁles because of the small sample numbers. Third, we
focused on HCM patients with MYBPC3 mutations, which had been
reported to be associated with delayed expression of hypertrophy
and a relatively good prognosis. It is not known whether the same
results would be obtained for patients with mutations in other
sarcomere genes such as cardiac beta myosin heavy chain gene
(MYH7) and cardiac troponin T gene. There is a recent review paper
focusing on genotype–phenotype association in patients with HCM
caused by sarcomere protein mutations, and some examples of
general associations between genotype and penetrance arereported for MYBPC3 (late onset and higher rate of incomplete
penetrance in females), MYH7 (age dependent penetrance), and
cardiac troponin I gene (high rate of incomplete penetrance) [9]. To
clarify the gender differences as the important modifying factors in
HCM, large-scale studies examining the relation between geno-
type, penetrance, disease severity, and prognosis are needed.
In conclusion, clinical manifestations differed between the
genders in our genotyped cohort of HCM patients: although
females with MYBPC3 mutations showed later onset of the disease,
female patients were more symptomatic at diagnosis and had
more frequent heart failure events once they had developed
hypertrophy.
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